# Olmesartan medoxomil

## Olmetec 40mg

| 藥物代碼           | OOLM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Hypertension: Treatment of hypertension with or without concurrent use of other antihypertensive agents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 副作用             | 1% to 10%: Central nervous system: Dizziness, headache Endocrine & metabolic: Hyperglycemia, hypertriglyceridemia Gastrointestinal: Diarrhea Neuromuscular & skeletal: Back pain, CPK increased Renal: Hematuria Respiratory: Bronchitis, pharyngitis, rhinitis, sinusitis Miscellaneous: Flu-like syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 禁忌               | Concomitant use with aliskiren in patients with diabetes mellitusCanadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2)                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 藥物保存方式       | 室溫                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 用法用量           | Dosing: Adult Hypertension: Oral: Initial: 20 mg once daily; if initial response is inadequate, may be increased to 40 mg once daily after 2 weeks. Usual dosage range: 20 to 40 mg daily. May administer with other antihypertensive agents if blood pressure inadequately controlled with olmesartan. Consider lower starting dose in patients with possible depletion of intravascular volume (eg, patients receiving diuretics). Dosing: Pediatric Hypertension: Children 6 to 16 years: Oral: 20 kg to <35 kg: Initial: 10 mg once daily; if initial response inadequate after 2 weeks, dose may be increased (maximum: 20 mg once daily) >=35 kg: Initial: 20 mg once daily; if initial response inadequate after 2 weeks, dose may be increased (maximum: 40 mg once daily) |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 孕期用藥建議       | Human data suggest risk in 2nd and 3rd trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 附帶說明           | [仿單] 懷孕婦女服用Olmetec會對胎兒造成傷害。在懷孕第2和第3期時，使用腎素－血管昇壓素系統的藥物使胎兒腎功能降低及增加胎兒和新生兒罹病率與死亡。 多數流行病學研究顯示，在懷孕第一期使用腎素－血管昇壓素系統藥物治療高血壓所產生的胎兒異常和使用其他種類的抗高血壓藥物並無分別。。 在動物生殖研究中，在器官形成過程中使用劑量低於母體毒性劑量的Olmetec進行治療，導致大鼠胚胎胎兒讀性增加。 一旦病患確定懷孕，需立即讓病患停用Olmetec。懷孕期間應考慮替代高血壓治療。                                                                                                                                                                                                                                                                                                                  |
| 哺乳期用藥建議     | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 附帶說明           | [仿單] 尚無相關資訊顯示是否人類乳汁中存在Olmesartan，影響哺乳胎兒或影響乳汁產生，但泌乳大鼠會分泌低濃度olmesartan到乳汁中。 因為其對哺乳胎兒可能產生的副作用，應評估藥物對母親的重要性，以決定要停止哺乳或停止用藥。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 注射劑給藥建議途徑 | AC, AC15, PC, PO, WM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

